about
IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndromeEmerging drugs for Guillain-Barré syndromePopulation Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-AnalysisGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisGuillain-Barré syndrome and variantsIVIG treatment and prognosis in Guillain-Barré syndromePharmacological treatment for pain in Guillain-Barré syndromeAcupuncture for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromePharmacological treatment for pain in Guillain-Barré syndromeMultidisciplinary care for Guillain-Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndromeAcupuncture for Guillain-Barré syndromeA Susceptible Mouse Model for Zika Virus InfectionGuillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or VaccinationStructural and functional characterization of human peripheral nervous system myelin protein P2Zika virus-associated neurological disorders: a reviewAccidental discovery and isolation of Zika virus in Uganda and the relentless epidemiologist behind the investigationsEvidence from Human and Animal Studies: Pathological Roles of CD8(+) T Cells in Autoimmune Peripheral NeuropathiesBiomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be ExploredRegulation of oxidative stress resistance in Campylobacter jejuni, a microaerophilic foodborne pathogenNeuro-glial interactions at the nodes of Ranvier: implication in health and diseasesAcute lung failureSialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regenerationAcute motor axonal neuropathy in a child with atypical presentation: a case reportThe natural antimicrobial carvacrol inhibits Campylobacter jejuni motility and infection of epithelial cellsPredicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic NeuritisMicrofluidic device for the formation of optically excitable, three-dimensional, compartmentalized motor unitsDelayed nerve stimulation promotes axon-protective neurofilament phosphorylation, accelerates immune cell clearance and enhances remyelination in vivo in focally demyelinated nervesGuillain-Barré Syndrome after Chikungunya InfectionA Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemSialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharidesUpdate on Guillain-Barré syndromeHealth-related quality of life in Guillain-Barré syndrome patients: a systematic reviewErythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathyQuinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules
P2860
Q21296685-F3F0A355-1D6B-4895-9CCD-41D48D28F287Q22241376-6DE449C2-64AA-4F90-90A6-5034C00572D3Q22241939-86E6D252-7D07-4D84-9D95-C2AC7734EE0FQ22251013-84A1A6CA-1664-4779-978F-FF0F1C37D93AQ22252353-EC24B045-E02E-4F97-8514-86EB076456DCQ22252627-0E47C6B4-5DDB-434C-AC32-E41A7CD97867Q24186580-C99BF2A8-77E4-40F1-AB14-C1998C23818DQ24187716-2034F98A-7677-4B84-B664-312068ED584BQ24193522-8C98782D-EEC2-4DE9-923E-EA905C28D7F1Q24200916-D9D74D22-C19E-4699-A41F-9146E4A5A86CQ24202100-EFD5283A-A30A-40D2-83B8-1F15332E60A5Q24202290-D5C690CD-23C1-4B76-976B-522F9F4507FFQ24234676-12B56173-817C-4612-8BAA-B6D36742200BQ24235600-0A7575BB-523D-48D6-87E8-3586758AB64FQ24236680-E9B20C18-3D25-4218-B4CD-979A8FF4188EQ24240577-EFC9C6FB-795F-4EA3-8C74-D9829BB8E82BQ24261180-f14a4e8d-4cc0-fe1f-0b9e-e6cc5d26dd4cQ24276196-6E36F862-7923-4B22-97B9-E67588CAF02BQ24307936-24250EE9-B86C-459B-89DD-D127F2407B20Q25115004-3E81440B-4FE1-4982-9372-ABDBFBC675FFQ26252276-187D6CDA-1989-47C1-9463-0A4C86F595C3Q26777185-017FCDED-8CA0-41CD-ABA2-5296BE592534Q26785669-A988E81D-4EB3-48CD-8B30-CF9F8C1D5C19Q26797357-39D7FDA8-447D-4BDC-A040-74A24A23FD1DQ26825224-E39D252F-E28D-4858-AB1A-97E6F72B9ACCQ26852173-88574050-FDC5-4B09-AB4B-66C88BAF69C6Q26995291-782B6BA5-3BD9-4EB6-94F7-29690464155EQ27007848-AA83C665-7D34-420C-AC70-169CF147FCFFQ27318344-F77AFD7F-3E68-458D-8859-42D865E25856Q27320796-FE4B7B00-123E-4AF8-AD07-D1B7F2156008Q27334752-0A8EF5BE-38C1-44C4-B183-D993DF683267Q27335500-E9F2A625-6F15-4C0D-8585-AB0665937676Q27488380-1BBE522D-0F68-423F-BA80-0850887FA2A7Q27883669-22BFB686-BACE-4CB9-B2BE-AEE5D9669977Q28075974-A223430E-C556-422F-98A8-B4CEB0CB7359Q28247592-E2F61300-5803-410A-B034-6AE4DFA17A67Q28293098-3EDF7FE7-79CD-4C53-B4CE-04AF50D15DFFQ28306474-13B1C8AE-E6F7-4559-A178-306C0CC914D7Q28477706-1817E18F-B331-45D1-8647-701ECF39A3A5Q28478607-B4AFA8AB-3649-4303-B375-D96943B0D2B6
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Guillain-Barré syndrome
@ast
Guillain-Barré syndrome
@en
Guillain-Barré syndrome
@en-gb
Guillain-Barré syndrome
@nl
type
label
Guillain-Barré syndrome
@ast
Guillain-Barré syndrome
@en
Guillain-Barré syndrome
@en-gb
Guillain-Barré syndrome
@nl
prefLabel
Guillain-Barré syndrome
@ast
Guillain-Barré syndrome
@en
Guillain-Barré syndrome
@en-gb
Guillain-Barré syndrome
@nl
P3181
P1433
P1476
Guillain-Barré syndrome
@en
P2093
David R Cornblath
Richard A C Hughes
P304
P3181
P356
10.1016/S0140-6736(05)67665-9
P407
P577
2005-11-05T00:00:00Z